MedTrace Logo

Mesenchymal Stem Cell for Osteonecrosis of the Femoral Head

NCT00813267 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2012-10-10

No results posted yet for this study

Summary

Mesenchymal Stem Cells (MSCs) have been shown to have immunosuppressive and repairing properties. Bone marrow mononuclear cells (BMMNCs) have revascularization properties and complimentary effects to MSCs. The investigators will infuse expanded autologous MSCs and BMMNCs into patients with osteonecrosis of the femoral head. The study purpose is to examine whether this treatment will result in improvement in osteonecrosis of the femoral head.

Conditions

  • Osteochondritis of the Femoral Head

Interventions

BIOLOGICAL

mesenchymal stem cell infusion

BIOLOGICAL

bone marrow mononuclear cell infusion

Sponsors & Collaborators

  • Jianming Tan

    lead OTHER

Principal Investigators

  • Jianming Tan, professor · Fuzhou General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-08-31
Completion
2015-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00813267 on ClinicalTrials.gov